Stryker price target raised to $92 from $87 at RW Baird Baird raised its price target on Stryker to $92 from $87 citing valuation, organic sales growth, and solid risk/reward. The firm has an Outperform rating on the stock.
Stryker downgraded to Underweight from Equal Weight at Barclays Barclays downgraded Stryker to Underweight saying shares look fully valued given its belief that large ortho consolidation is less likely in the near term. The firm points out its channel checks on MAKO have been mixed and that competition from other robotic surgery solutions is likely. It raised its price target for shares to $92 from $88.